Highlights

• The study identifies NAV2 as a novel contributor to rheumatoid arthritis (RA) pathogenesis via activation of the Wnt/β-catenin and SSH1L/Cofilin-1 signaling pathways. 
• It highlights the STAT3-NAV2 axis as a newly proposed therapeutic target involved in synovial inflammation and joint damage.
• The article emphasizes the unexplored role of transcription factor GATA4 in promoting RA angiogenesis, suggesting it as a potential intervention target

Summary

This article provides a comprehensive review of the molecular mechanisms driving rheumatoid arthritis (RA) and highlights potential therapeutic targets. It outlines the disease’s historical context, epidemiology, symptoms, and risk factors, emphasizing the interplay of genetic, environmental, and epigenetic influences.

The research focuses on critical signaling pathways (such as JAK-STAT, MAPK, PI3K-AKT, SYK, Wnt, and Notch) that are implicated in RA progression, along with key immune cells like fibroblast-like synoviocytes (FLS) and T and B lymphocytes. The researchers explore how dysregulation in these pathways contributes to inflammation, joint degradation, and systemic complications, and they review current and emerging drugs targeting these mechanisms.

By integrating insights from molecular biology and immunology, this study supports comprehensive information about the development of more precise and effective RA therapies.

Q. Ding et al., “Signaling pathways in rheumatoid arthritis: implications for targeted therapy,” Sig Transduct Target Ther, vol. 8, no. 1, p. 68, Feb. 2023, doi: 10.1038/s41392-023-01331-9.